이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study to Evaluate the Efficacy of a Postbiotic Supplement on Menopausal Symptoms in Premenopausal Women (RESW101)

2026년 5월 28일 업데이트: Able Biolabs, LLC

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of a Postbiotic Supplement (resW) on Menopausal Symptoms and Hormonal Balance in Premenopausal Women

The goal of this consumer health study is to evaluate the effect of resW™ Perimenopause Postbiotic on menopausal symptom severity, menopause-related quality of life, and selected microbiome-related outcomes in generally healthy perimenopausal women aged 35 to 55 years.

Participants will be randomized to receive either the active supplement or placebo daily for 4 weeks. Participants will complete electronic questionnaires at baseline and during the study. A predefined subset of participants will also complete stool and vaginal sample collection at baseline and Week 4.

연구 개요

상세 설명

This is a randomized, double-blind, placebo-controlled, parallel-group consumer health study evaluating the effect of resW™ Perimenopause Postbiotic in generally healthy perimenopausal women aged 35 to 55 years.

Eligible participants will be randomized in a 1:1 ratio to receive either resW™ Perimenopause Postbiotic or placebo for 4 weeks. Participants will take 2 capsules daily and complete electronic study questionnaires through the Chloe app. Menopausal symptom severity and menopause-related quality of life will be assessed using the Greene Climacteric Scale and Cervantes Short Form at baseline and Week 4, with an interim Greene Climacteric Scale assessment at Week 2.

A predefined microbiome substudy subset of approximately 20 participants will complete stool and vaginal sample collection at baseline and Week 4. These samples will be used to evaluate exploratory changes in stool microbiome composition, vaginal microbiome composition, and vaginal pH.

Safety and tolerability will be monitored throughout the study through adverse event reporting, compliance tracking, and participant-reported feedback.

연구 유형

중재적

등록 (실제)

80

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Texas
      • Dallas, Texas, 미국, 75247
        • Able Biolabs LLC

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인

건강한 자원 봉사자를 받아들입니다

설명

Inclusion Criteria:

  • Provide voluntary, signed, and dated informed consent.
  • Female, aged 35 to 55 years, inclusive.
  • Currently experiencing perimenopausal symptoms, such as hot flashes, mood changes, sleep disturbance, or irregular cycles.
  • In generally good health as determined by self-reported medical history.
  • Agree to maintain existing diet, exercise, and lifestyle patterns throughout the study period.
  • Able and willing to comply with all study procedures, including electronic consent, app-based data entry, and study questionnaires.
  • Participants selected for the microbiome substudy must be willing to complete stool and vaginal sample collection.
  • Females of childbearing potential must agree to use a medically acceptable form of birth control during the study.
  • Agree to refrain from taking other probiotic, prebiotic, postbiotic, hormonal, or menopause-support supplements during the study.
  • Have reliable internet or smartphone access.

Exclusion Criteria:

  • Currently pregnant, planning to become pregnant, or breastfeeding.
  • History or current diagnosis of gynecologic disorders or other conditions affecting hormonal balance.
  • Current or recent use of hormone replacement therapy or hormonal medications.
  • History of unstable or newly diagnosed cardiovascular, hepatic, renal, or significant metabolic disorders.
  • Known gastrointestinal disease or condition affecting absorption or metabolism.
  • Known allergy or sensitivity to any ingredient in the study supplement.
  • Current participation in another clinical study involving an investigational product or device, or participation in such a study within the past 30 days.
  • Any other medical or psychiatric condition that, in the opinion of the investigator or study team, could interfere with study participation, compliance, or interpretation of study results.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 위약
Inactive supplement
실험적: 보충
Active supplement

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Greene Climacteric Scale total score from baseline to Week 4
기간: Baseline to Week 4
Change from baseline to Week 4 in the Greene Climacteric Scale total score. The Greene Climacteric Scale is a 21-item questionnaire assessing climacteric symptoms. Total scores range from 0 to 63, with higher scores indicating greater climacteric symptom severity, which is a worse outcome.
Baseline to Week 4
Changes in gut microbiota composition associated with hormonal health
기간: 4 weeks
Change from baseline to Week 4 in gut microbiota composition assessed using stool sample microbiome sequencing. Gut microbiota composition will be evaluated by measures including microbial taxonomic relative abundance and diversity metrics derived from sequencing data. This outcome will assess changes in the composition of bacterial taxa in stool samples associated with hormonal health.
4 weeks
Change in Cervantes Short Form total score from baseline to Week 4
기간: Baseline to Week 4
Change from baseline to Week 4 in the Cervantes Short Form Scale total score. The Cervantes Short Form Scale is a validated menopause-specific quality-of-life questionnaire assessing menopause-related quality of life across physical, psychological, and aging-related domains. Total scores range from 0 to 100, with higher scores indicating poorer menopause-related quality of life, which is a worse outcome.
Baseline to Week 4

2차 결과 측정

결과 측정
측정값 설명
기간
Change in stool microbiome alpha diversity from baseline to Week 4
기간: Baseline to Week 4
Change from baseline to Week 4 in stool microbiome alpha diversity, assessed using diversity indices such as the Shannon diversity index, Simpson diversity index, or observed amplicon sequence variants/species richness, in participants enrolled in the microbiome substudy.
Baseline to Week 4
Change in stool microbial taxonomic composition from baseline to Week 4
기간: Baseline to Week 4
Change from baseline to Week 4 in the relative abundance of stool microbial taxa, assessed using stool sample microbiome sequencing, in participants enrolled in the microbiome substudy.
Baseline to Week 4
Change in vaginal microbiome alpha diversity from baseline to Week 4
기간: Baseline to Week 4
Change from baseline to Week 4 in vaginal microbiome alpha diversity, assessed using diversity indices such as the Shannon diversity index, Simpson diversity index, or observed amplicon sequence variants/species richness, in participants enrolled in the microbiome substudy.
Baseline to Week 4
Change in relative abundance of vaginal microbial taxa from baseline to Week 4
기간: Baseline to Week 4
Change from baseline to Week 4 in the relative abundance of vaginal microbial taxa, including Lactobacillus species and bacterial vaginosis-associated taxa, assessed using vaginal sample microbiome sequencing, in participants enrolled in the microbiome substudy.
Baseline to Week 4
Change in vaginal pH from baseline to Week 4
기간: Baseline to Week 4
Change from baseline to Week 4 in vaginal pH, measured from vaginal samples using a pH test method, in participants enrolled in the microbiome substudy. Vaginal pH is measured on a continuous scale, with higher values indicating greater vaginal alkalinity.
Baseline to Week 4

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 4일

기본 완료 (실제)

2026년 5월 15일

연구 완료 (실제)

2026년 5월 27일

연구 등록 날짜

최초 제출

2026년 4월 29일

QC 기준을 충족하는 최초 제출

2026년 4월 29일

처음 게시됨 (실제)

2026년 5월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 28일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Placebo에 대한 임상 시험

구독하다